After finishing at $15.89 in the prior trading day, Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $15.64, down -1.57%. On the day, 881392 shares were traded.
Ratios:
Our goal is to gain a better understanding of VRDN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.26 and its Current Ratio is at 18.26. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On June 14, 2023, BTIG Research started tracking the stock assigning a Buy rating and target price of $46.
On May 30, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $44.RBC Capital Mkts initiated its Outperform rating on May 30, 2023, with a $44 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 22 ’24 when Fairmount Funds Management LLC bought 476,190 shares for $21.00 per share. The transaction valued at 9,999,990 led to the insider holds 1,839,954 shares of the business.
Meisner Lara sold 27 shares of VRDN for $765 on Jun 16 ’23. The Chief Legal Officer now owns 29,971 shares after completing the transaction at $28.35 per share. On Jun 15 ’23, another insider, Meisner Lara, who serves as the Chief Legal Officer of the company, sold 2,269 shares for $28.02 each. As a result, the insider received 63,577 and left with 29,971 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3166.85 while its Price-to-Book (P/B) ratio in mrq is 3.59.
Stock Price History:
Over the past 52 weeks, VRDN has reached a high of $30.30, while it has fallen to a 52-week low of $10.93.
Shares Statistics:
A total of 62.77M shares are outstanding, with a floating share count of 55.85M. Insiders hold about 11.02% of the company’s shares, while institutions hold 90.25% stake in the company.
Earnings Estimates
Its stock is currently analyzed by VeriSign, Inc. different market analysts. The consensus estimate for the next quarter is $29.80, with high estimates of $0.15 and low estimates of $15.64.
Analysts are recommending an EPS of between $Basic Materials and $Healthcare for the fiscal current year, implying an average EPS of $Financial Services.
